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Local cerebral metabolic rate for glucose was studied with '8F-2-fluorr+2-deoxy-D-glucose and positron emission to- 
mography (PET) in 22 patients with Friedreichs ataxia and 23 age-matched normal control subjects. The diagnosis of 
Friedreich's ataxia was established by the history and physical findings and by excluding other diseases through 
laboratory investigations. PET studies revealed a statistically significant widespread increase of local cerebral meta- 
bolic rate for glucose in the brains of patients with Friedreich's ataxia who were still ambulatory, in comparison with 
normal control subjects. Nonambulatory patients with Friedreich's ataxia, in comparison with normal control subjects, 
had significantly increased local cerebral metabolic rates for glucose in the caudate and lenticular nuclei, but not in the 
other structures studied. The rate was significantly greater in ambulatory patients with Friedreich's ataxia than in 
nonambulatory patients in all structures studied except the caudate and lenticular nuclei. The data suggest that early 
in the course of Friedreich's ataxia, the local cerebral metabolic rate for glucose is increased extensiveIy in the central 
nervous system, and as the disease progresses, it decreases in a regionally specific manner. 
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Friedreich's ataxia (FA) is a chronic progressive neu- 
rological disorder inherited as an autosomal recessive 
trait with the abnormal gene located on  chromosome 
9 11-61. The disorder usually begins before puberty 
with progressive ataxia of gait and muscle weakness. 
As these symptoms worsen, other disturbances ap- 
pear and include: limb ataxia; dysarthria; scoliosis; pes 
cavus; loss of position sense, vibration sense, and light 
touch sensation of the limbs; loss of the deep tendon 
reflexes; and the appearance of extensor plantar re- 
sponses 11-41. Nearly all patients eventually require a 
wheelchair because of progressive weakness and ataxia 
of the legs. A cardiomyopathy occurs and usually ac- 
counts for death by middle age [7). Some patients with 
FA develop diabetes mellitus IS]. 
The principal neuropathological changes in FA in- 
volve the peripheral nerves and the spinal cord {l ,  
4, 8-1 1). Degeneration occurs in peripheral sensory 
nerves, dorsal root ganglia, and dorsal roots. Within 
the spinal cord, there is degeneration of posterior col- 
umns, lateral corticospinal tracts, and dorsal and ven- 
tral spinocerebellar tracts. The cerebellum and brain- 
stem have been described as normal { 1 1 ], but in some 
patients there is shrinkage of the pons and medulla C9, 
lo]. Occasional patients show patchy atrophy of the 
Purkinje cells, and in many there is degeneration of 
neurons in the dentate nuclei [lo]. Degenerative 
changes may also occur in the reticular and vestibular 
nuclei of the brainstem C9, lo]. 
Many biochemical abnormalities have been reported 
in fibroblasts, leukocytes, or muscle tissue from 
patients with FA, but some of these findings axe con- 
troversial. Deficiencies in activity of the pyruvate de- 
hydrogenase complex and alpha ketoglutarate dehy- 
drogenase complex have been described {12, 131. 
Other abnormalities reported include deficiency of 
mitochondrial malic enzyme activity [14, 151 and of 
serum lipoprotein lipase ElGI and abnormalities of 
erythrocyte membrane phospholipids, plasma cate- 
cholamines, and leukocyte glutamate dehydrogenase 
activity C51. 
In most patients with FA, the characteristic history 
and physical findings make the diagnosis relatively 
straightforward El-41. In patients with progressive 
ataxia whose history and physical findings differ from 
those typical of FA, however, the diagnosis is often 
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difficult and requires extensive laboratory testing. The  
differential diagnosis of these patients includes mal- 
formations, degenerations, demyelinative diseases, 
neoplasms, remote effects of neoplasms, vascular dis- 
eases, and metabolic abnormalities { 1, 171. 
Positron emission tomography (PET) with I8F-2- 
fluoro-2-deoxy-D-glucose (ISF-FDG) has been used 
to study local cerebral metabolic rate for glucose 
(1CMRglc) in the central nervous system of patients 
with olivopontocerebellar atrophy, another degenera- 
tive disease causing ataxia [18-20}. A distinctive pat- 
tern of hypometabolism was found in the brainstem 
and cerebellum without involvement of the cerebral 
cortex, basal ganglia, or thalamus. T h e  present study 
was undertaken to determine whether a unique pat- 
tern might be found in patients with FA as well. De- 
generation of spinocerebellar afferents, which termi- 
nate in the granule cell layer of the vermis [l], might 
be expected to result in cerebellar hypometabolism 
principally within vermal regions. In addition, degen- 
eration of second-order sensory neurons originating in 
the gracile and cuneate nuclei as well as transynap- 
tic effects from degeneration of first-order sensory 
neurons {9, 111 might be expected to result in loss of 
synapses and hypometabolism in the thalamus. Sur- 
prisingly, the results of this study demonstrated wide- 
spread cerebral hypermetabolism in patients with FA 
who were still ambulatory, with metabolic rates close 
to normal control levels in patients with FA who were 
no longer ambulatory. Preliminary descriptions of this 
work have been published I2 1-24]. 
Materials and Methods 
We studied 22 patients with FA and 23 normal control sub- 
jects (Table I). The studies were approved by the institu- 
tional review board, and informed consent was obtained 
from all subjects. Among the patients with FA, the duration 
of illness averaged 18 * 7 years and ranged from 6 to 30 
years. Ten patients had one or more affected siblings, 11 had 
no affected relatives, and 1 patient had a cousin who may 
have FA. The normal control subjects had no history of 
neurological disease and no significant abnormalities on 
neurological and general physical examination. The patients 
and normal control subjects were taking no medication 
known to affect central nervous system (CNS) function or to 
cause CNS side effects and subjects with a history of alcohol- 
ism were excluded. 
The diagnosis of FA was made on the basis of the history, 
physical examination, neurological examination, and labora- 
tory tests to exclude other diseases. Required findings in- 
cluded ataxia of limb movements and of gait if the patients 
were still ambulatory; weakness of the lower extremities; 
ataxic dysarthria; decreased or absent muscle stretch reflexes 
in the lower extremities; extensor plantar reflexes; and de- 
creased position and vibration sense in the lower extremities. 
The diagnosis was supported by the findings of scoliosis, pes 
cavus, decreased pinprick and light touch sensation in the 
distal parts of the extremities, and atrophy of the distal limb 
Table 1 .  Average Ages of the Subjects Studied 
Patients with 
Friedreich's 
Control Subjects Ataxia 
n (+ SD) n (?  SD) 
Age (yr) Age (yr) 
Male 13 2% ? 5 9 3 0 * 7  
Female 10 34 r 9 13 31 ? 7 
All subjects 23 30 ? 8 22 30 k 7 
muscles. All patients met the diagnostic criteria of Harding 
E2). All patients also met the criteria of Geoffroy and col- 
leagues [25] except one whose age at onset (23 years) is 
above their limit of 20 years; elimination of this patient from 
the analysis did not substantially alter the findings of this 
study. Patients with an atypical history or examination were 
excluded from the study before their data were analyzed. 
The patients excluded were a 28-year-old man who had pre- 
served position sense and vibration sense in the legs, a 49- 
year-old man who had intact deep tendon reflexes in the legs, 
and a 30-year-old woman who did not have dysarthria. Anal- 
yses of duration of illness excluded 6 patients who were not 
the first member of their family diagnosed with FA, to avoid 
the bias that may be introduced in determining disease onset 
when another family member has been previously diagnosed 
with FA. 
PET studies of normal control subjects and patients with 
FA were performed with the subjects lying supine, awake, 
immobile, not speaking, and blindfolded in a quiet room. 
They were maintained under these conditions from 5 min- 
utes before injection until completion of the scan. '*F-FDG 
was synthesized by an adaptation of the method of Shiue 
and associates {26] or of Hamacher and coworkers 1271. 
Radiochemical purity was greater than 95%. Scans were per- 
formed 30 to 75 minutes after intravenous injection of 5 to 
10 mCi of "F-FDG and lasted for 8 to 12 minutes. Each 
subject was placed in a headholder that maintained the head 
immobile throughout the study. The head was aligned along 
the orbitomeatal line with a laser. PET scans were performed 
with a TCC PCT 4600A tomograph having an inplane reso- 
lution of 11-mm full width at half maximum (FWHM) and a 
Z-axis resolution of 9.5-mm PWHM. Five planes with 11.5- 
mm center-to-center separation were imaged simultaneously. 
Four sets of scans were taken per patient, including two 
interleaved sets through lower brain levels and two inter- 
leaved sets through higher brain levels for a total of 20 slices, 
each separated by 5.75 mm. Attenuation correction was cal- 
culated by fitting ellipses to the contour of the scalp outline 
and modified to account for attenuation from the headholder 
and skull. Blood samples were collected from one radial 
artery. 1CMRglc was calculated with a three compartment 
model and single-scan approximation, with gray matter ki- 
netic constants derived from normals. 
Regions of interest (ROIs) were studied in the cerebral 
cortex, basal ganglia, thalamus, cerebellar hemispheres, cere- 
bellar vermis, mesencephalon, and pons. Data from the ce- 
rebral cortex were obtained by measuring ICMRglc in the 
cortical rim from six consecutive slices beginning with the 
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Table 2. Local Cerebral Metabolic Rate for Glucose (in mgl100 gmlmin) in All Subjects' 
Patients with 
Structure Control Subjects (n = 23) Friedreich's Ataxia (n = 221 b Valiie 
Cerebral cortex 5.80 -+ 1.07 6.64 t 1.30 0.02 
Caudate nucleus 6.20 -t 1.32 7.91 4 1.56 0.0003 
Lenticular nucleus 6.82 c 1.44 8.10 2 1.64 0.008 
Thalamus 6.81 t 1.46 7.29 -1- 1.87 NS 
Cerebellar vermis 5.10 2 1.05 5.55 -+ 1.33 NS 
Left cerebellar hemisphere 5.59 5 1.20 6.04 -1- 1.61 NS 
Right cerebellar hemisphere 5.47 t 1.18 6.10 2 1.66 NS 
Mesencephalon 5.06 z 1.02 5.54 -+ 1.21 NS 
Pons 4.10 2 0.79 4.46 -1- 1.05 NS 
"Values given are the mean t SD; statistical test, Student's t test. 
NS = not significant; p > 0.10. 
lowest slice containing the basal ganglia. This was accom- 
plished with an algorithm that detects the outer edge of the 
cortical rim on images that have been passed through a con- 
trast-enhancing filter. The algorithm then identifies a cortical 
strip on the original image that extends inward from this 
edge until either the metabolic rate drops below the value on 
the outer edge of the rim or the strip reaches a width of 15 
mm. The mean metabolic rate was computed for each of the 
ROIs and the final value was a weighted mean of the values 
from the six individual slices. The ROIs for the basal ganglia 
consisted of an 11 x 11-mm square on each side of the 
caudate nucleus and an 11 x 15-mm parallelogram on each 
side of the lenticular nucleus (putamen and globus pallidus). 
The other ROIs consisted of an 11 x 11-mm square on each 
side of the thalamus, a 22 x 11-mm parallelogram on each 
cerebellar hemisphere, and an 11 x 18-mm rectangle on the 
cerebellar vermis. For analysis of the mesencephalon and 
pons, a three-dimensional image set consisting of planes 
spaced at 3.75 mm intervals in the rostrocaudal direction was 
generated by interpolation of the two-dimensional images. A 
midsagittal image, 11 mm in thickness, was derived from thls 
image set. The resulting volume of interest for the mesen- 
cephalon was an 11 X 11 X 7.5-mm right parallelepiped, 
while that for the pons was a 15 x 11 X 15-mm right 
parallelepiped. The ROIs were centered over a local peak in 
1CMRglc. For reference, an individual image element (pixel) 
is 3.75 x 3.75 mm in size. Data were obtained from two 
slices containing the cerebellum and branstem, from one 
slice containing the thalamus, and from one slice containing 
the basal ganglia. ROIs from the cerebellar vermis were pos- 
terior to the fourth ventricle, as determined by direct visual- 
ization of the ventricle. 
An index of brain volume was developed to compare the 
patients with FA and the control subjects. The mean cross- 
sectional area of the brain from the two largest adjacent PET 
slices was measured, and this value was raised to the 312 
power. 
Statistical analysis was performed with two-tailed Student's 
t tests, analysis of variance, the Newman-Keuls test, and 
Spearman rank correlation analysis. A p value of 0.05 or less 
was taken as significant. 
Table 3. Comparison 4 Ambulatory and Nonambulatory 
Patients with Friedreichk Ataxia" 
Ambulatory Nonambulatory p Value 
Ageb 30 r 7 30 f 7 NS 
Age of onset 17 ? 4 10 2 4 0.007 
Duration (vr)' 15 t 5 21 f 5 0.08 
(yrY 
"Values given are the mean * SD; statistical test, Student's t test. 
bn = 8 ambulatory, 14 nonambulatory patients. 
'n = 5 ambulatory, 11 nonambulatory patients (only first patient>, 
affected in a family are included). 
NS = not significant;p = 0.95. 
Results 
Mean lCMRglc for the entire FA group was 7% to 
28% greater than that of the control group for the 
structures analyzed. Statistical testing revealed signif- 
icantly increased lCMRglc in the patients with FA, 
compared with the control subjects, in the cerebral 
cortex, caudate nucleus, and lenticular nucleus, but not 
in the thalamus, cerebellar vermis, cerebellar hemi- 
spheres, or brainstem (Table 2). 
To examine the relationship between the severity of 
the neurological disorder and ICMRglc, we divided the 
patients into two groups, ambulatory and nonambula- 
tory. The two groups were equal in age at the time of 
the study, but the ambulatory patients had a signifi- 
cantly later age of onset than did the nonambulatory 
patients (Table 3). Mean lCMRglc for the ambulatory 
group was 23% to 34% greater than that of the con- 
trol group for the structures analyzed (Table 4 ,  Fig 1). 
lCMRglc in the ambulatory group was significantly in- 
creased, compared with the normal control subjects, in 
all structures studied except the pons. In contrast, 
mean lCMRglc for the nonambulatory group ranged 
752 Annals of Neurology Vol 28 N o  6 December 1990 
Table 4. Local Cerebral Metabolic Rate for Glucose (in ?ng/LOO gdrnin) i?z Control Subjects and 
Ambulatory and Nonambulato y Patients with Fraedreich’s Ataxia (FA)” 
Ambulatory Nonambulatory 
Control Patients Patients 
Subjects with FA with FA 
Structure (n = 23) (n = 8) p Valueb (n = 14) p Value‘ p Valued 
Cerebral cortex 5.80 * 1.07 7.24 2 0.80 0.01 6.29 k 1.42 NS 0.07 
Caudate nucleus 6.20 1.32 8.30 t 1.23 0.002 7.68 t 1.72 0.005 NS 
Lenticular nucleus 6.82 t 1.44 8.51 f 1.53 0.03 7.86 & 1.71 0.03 NS 
Thalamus 6.81 f 1.46 8.58 t 1.43 0.007 6.55 ? 1.71 NS 0.01 
Cerebellar vermis 5.10 * 1.05 6.28 f 0.79 0.04 5.13 & 1.41 NS 0.03 
Left cerebellar hemisphere 5.59 t 1.20 7.09 * 1.03 0.007 5.45 f 1.61 NS 0.02 
Right cerebellar hemisphere 5.47 2 1.18 7.17 * 1.02 0.008 5.49 2 1.67 NS 0.006 
Mesencephalon 5.06 * 1.02 6.22 ? 0.93 0.03 5.15 & 1.20 NS 0.03 
Pons 4.10 f 0.79 5.09 2 0.67 0.07 4.10 k 1.07 NS 0.03 
“Values given are the mean ? SD; statistical test, Newman-Keuls. 
bComparison of normal control subjects with ambulatory patients with FA. 
‘Comparison of normal control subjects with nonambulatory patients with FA. 
dComparison of ambulatory with nonambulatory patients with FA. 
NS = not significanqp > 0.20. 
from 4% less to 24% greater than that of the normal 
control group for the structures analyzed. lCMRglc 
was significantly higher in nonambulatory patients than 
in normal controls for the basal ganglia, but not for 
the other structures (see Table 4). 1CMRglc was sig- 
nificantly greater in the ambulatory patients than in the 
nonambu!atory group in all structures studied except 
for the cerebral cortex, where the difference ap- 
proached significance, and in the basal ganglia (see 
Table 4). The differences between control, ambula- 
tory, and nonambulatory groups are portrayed in Fig- 
ure 2, in which the data in the two FA groups are 
normalized to the values of the control group. 
To determine whether differences in lCMRglc be- 
tween the sexes contributed to the observed differ- 
ences between groups, we compared ICMRglc in pa- 
tients with FA and normal control subjects using 
analysis of variance with sex and disease group as f x -  
tors (Table 5). The results revealed that sex was not a 
significant factor for any region. Disease group was a 
significant factor for the cerebral cortex, caudate nu- 
cleus, and lenticular nucleus, but not for the thalamus, 
cerebellum, or brainstem. There was no significant in- 
teraction between disease group and sex for ICMRglc 
values from any region. 
Since FA is a progressive disorder, we examined 
lCMRglc as a function of age and duration of symp- 
toms. lCMRglc declined significantly with increasing 
age in the caudate nucleus (Spearman rank correlation 
coefficient r, = -0.46, p = 0.03) and lenticular nu- 
cleus (T, = -0.48, p = 0.02), but ICMRglc did not 
correlate Significantly with age for the other brain re- 
gions analyzed (rs = -0.29 to -0.08, p > 0.20). 
lCMRglc did not correlate with duration of symptoms 
for any region (rS = - 0.33 to + 0.06, p > 0.20) in the 
16 patients who were the first in the family to develop 
the disease. 
Patients with FA are thought to have an increased 
incidence of diabetes mellitus [ S } ,  and elevation of the 
plasma glucose levei could influence measurements of 
ICMRglc in the CNS. Only 1 patient, who was nonam- 
bulatory, had diabetes mellitus, and his fasting blood 
glucose was elevated (326 mg/lOO dl). His ICMRglc 
values averaged approximately one standard deviation 
(SD) above the mean of the nonambulatory group. If 
this patient’s results were eliminated, the data pre- 
sented in Tables 2 and 4 would change little, and all 
significant results in these tables would remain signif- 
icant. Mean fasting blood glucose levels were 87 ? 8 
mg/dl (mean ? SD) in the normal control group and 
86 _+ 8 mg/dl in the FA group, excluding the diabetic 
patient. 
The brain volumes of the patients with FA were 
compared with those of the normal control subjects. In 
the patients with FA (n = 22), the mean volume index 
was 2,080 2 157 cm3, whereas in the normal controls 
(n = 23), the mean volume index was 2,269 * 230 
cm3. These values are significantly different (t = 3.22, 
p < 0.003). This difference was found in both males 
and females (male FA: n = 9, 2,176 -C 159 cm3, 
versus male control subjects: n = 13, 2,390 & 210 
cm3, t = 2.59,p = 0.02;femaleFA: n = 13,2,013 ? 
118 cm3, versus female control subjects: n = 10, 
2,111 & 146 cm3, t = 1.78, p = 0.09). The mean 
volume index for the ambulatory patients with FA 
(n = 8, 2,081 _+ 175 cm3> was not significantly differ- 
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Fig  I. PET scans shwing cerebral glucose utilization as detected 
with ‘8F-2-~uoro-2-deoxy-~glucose. Scans in A, B, and C show 
a horizontal section at the level ofthe cerebellum and the base of 
the temporal and frontal lobes. Scans in D, E, and F show the 
level of the basal ganglia and thalamus. Color bars indicate the 
rate of glucose gtilization (mgll00 gmlmin). (A and D) Control 
subject, female, age 24 years. (B and E) Ambulatory patient 
with Friedreich’s ataxia, female, age 25 years. (C and F )  
Nonambukztory patient with Friedreich’s ataxia, female, age 29 
years. Note the glucose hypermetabolism in the ambulatory pa- 
tient with Friedreich’s ataxia compared with the control subject 
and the nonambdato y patient with Friedreich’s ataxia. 
ent from the mean volume index for the nonambula- 
tory patients with FA (n = 14, 2,079 k 15 1 cm3, t = 
0.02, p > 0.5). 
Discussion 
This study provided evidence of cerebral glucose hy- 
permetabolism extensively in the CNS of patients with 
FA who are still ambulatory in comparison with age- 
and sex-matched normal control subjects. Significantly 
increased ICMRglc also was found in nonambulatory 
patients with FA in comparison with normal control 
subjects, but only within the basal ganglia. Ambulatory 
451 
R Cerebral Cortex 
=Caudate Nucleus 






Fig 2. Mean local cerebral metabolic rate for glucose (1CMRgkc) 
relative to the values of the normal control subjectsfor ambula- 
tory and nonambulatovy pattents with Friedreich’s ataxia. Error 
bars represent the standard error of the mean. 
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Table 5 .  Local Cerebral Metabolic Rate f i r  Glucose (in mgll00 gmlmin) in Males and Femalesa 
Male Control Female Control Male Patients Female Patients 
Subjectsb Subjectsb with FAb with FAb 
Structure (n = 13) (n = 10) (n = 9) (n = 13) p Value' 
Cerebral cortex 5.54 k 0.92 6.14 k 1.21 6.42 k 1.07 6.79 5 1.45 0.04 
Caudate nucleus 5.92 f 1.17 6.56 ? 1.47 7.60 2 1.40 8.12 f 1.68 0.0006 
Lenticular nucleus 6.50 f 1.24 7.23 2 1.64 7.95 2 1.42 8.20 k 1.83 0.014 
Thalamus 6.24 f 1.03 7.54 f 1.67 6.90 5 1.45 7.55 f 2.12 NS 
Cerebellar vermis 4.75 ? 0.87 5.56 Ifr 1.13 5.37 f 1.06 5.67 f 1.51 NS 
Left cerebellar hemisphere 5.26 2 1.08 6.01 ? 1.27 5.66 2 1.11 6.31 +- 1.88 NS 
Right cerebellar hemisphere 5.13 5 1.08 5.91 f 1.20 5.67 ? 1.17 6.40 1.91 NS 
Pons 3.88 ? 0.69 4.39 f 0.86 4.28 ~fr 0.97 4.58 ~fr 1.12 NS 
"Values given are the mean 2 SD; statistical test, analysis of variance with disease group and sex as factors. 
bSex is not a significant factor for any region. 
cp Value: disease as factor (comparison of disease group for male and female normal control subjects versus male and female patients with FA). 
FA = Friedreich's ataxia; NS = not significant, p > 0.20. 
Mesencephalon 4.63 f 0.72 5.62 ? 1.10 5.37 f 1.09 5.65 2 1.31 NS 
patients had significantly higher 1CMRglc than nonam- 
bulatory patients for all structures except the basal gan- 
glia. Neither the sexes nor the ages of the patients was 
a significant factor in the findings. 
The age of onset of symptoms was signhcantly 
greater in patients who were ambulatory at the time of 
the study than in the nonambulatory patients. This dif- 
ference is most likely explained on the basis of selec- 
tion bias. Age 18 was the minimum age at which nor- 
mal control subjects and patients were eligible for our 
study in accordance with institutional policy regarding 
studies with radionuclides in children. In a slowly pro- 
gressive disease such as FA, patients who remain am- 
bulatory over the age of 18 are likely to be those with a 
late age of onset. It may also be that our ambulatory 
patients had intrinsically milder disease or slower pro- 
gression of disease than our nonambulatory patients. 
We cannot exclude the possibility that our group of 
ambulatory patients represents, in part, a different 
phenotype from the nonambulatory group. Variations 
in phenotype are known to occur even in kindreds that 
inherit the same abnormal gene {8, 25, 28, 291. 
Our findings may indicate that, early in the course of 
FA, glucose metabolic rate is increased broadly in the 
CNS, and as the disease progresses, metabolic rate 
decreases. The decrease is nonuniform, with the basal 
ganglia maintaining a higher metabolic rate with dis- 
ease progression than the other structures studied. The 
increased metabolism may reflect a fundamental bio- 
chemical defect in FA, while the decline in metabolic 
rate with disease progression may be due to loss of 
neurons and synaptic terminals. This would explain the 
finding of more substantially increased metabolic rate 
in ambulatory than in nonambulatory patients, since 
typically with disease progression, FA patients lose the 
ability to walk. 
The possibility that the finding of glucose hyper- 
metabolism is artifactual must be considered. The ma- 
jor potential sources of error are FA-specific alter- 
ations in 18F-FDG rate constants between subject 
groups, and smaller brain size in patients with FA than 
in normal control subjects. The possibility that FA- 
specific alterations in the rate constants affected our 
data seems unlikely, since changes in rate constants 
that cause major errors in the single-scan approxima- 
tion used to evaluate lCMRglc have not been found in 
any progressive degenerative neurological disease. We 
found that patients with FA have smaller brain vol- 
umes than normal control subjects; however, this 
finding is not likely to account for the glucose hyper- 
metabolism. Hatazawa and colleagues {so] found in 
normal subjects that lCMRglc is inversely proportional 
to brain volume. Since the small brain volume in pa- 
tients with FA presumably results from their disease 
process, it is questionable whether the same relation- 
ship applies to them. This relationship clearly does not 
apply to patients with Alzheimer's disease, who have a 
decreased volume associated with hypometabolism. 
Even if this relationship were to apply to patients with 
FA, the 75% decrease in brain volume compared to 
normal subjects would account for only a 7% increase 
in lCMRglc, yet we observed a 23% to 34% increase 
in lCMRglc in ambulatory patients with FA, compared 
with normal subjects. 
The demonstration of CNS glucose hypermetabo- 
lism in patients with FA might be explained by abnor- 
malities of carbohydrate metabolism in this disease 
{31}. Many patients with FA have been found to have 
difficulty with the metabolism of pyruvate {32-341. 
Following a glucose load, patients with FA typically 
have elevated blood pyruvate levels [l3}, and pyruvate 
clearance is delayed {341. The precise defect in FA 
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responsible for abnormalities of carbohydrate metabo- 
lism is controversial. Deficiencies of the pyruvate de- 
hydrogenase complex, alpha ketoglutarate, and mito- 
chondrial malic enzyme in FA have been found in 
some laboratories 112, 15 ,  35-37] but not in others 
C32, 38-40]. Perhaps some of the discrepancies in 
findings relate to the stage of the disease in which the 
patients' tissues are examined or to different pheno- 
types of the disease. 
Blass and associates [311 suggested that the charac- 
teristic biochemical abnormality in FA and related con- 
ditions results from damage to mitochondria rather 
than deficiency of a specific mitochondrial enzyme. 
Damaged mitochondria may explain some of the con- 
troversial biochemical findings 13 1, 411. Mitochondria1 
abnormalities have been invoked to explain much of 
the pathophysiology of this disease 130, 331 and a mi- 
tochondrial disorder could explain the findings in the 
present study. Glucose hypermetabolism may reflect a 
needed increase in glycolytic rate because of difficulty 
in the oxidation of pyruvate to enter the Krebs tricar- 
boxylic acid cycle. Future studies of the mitochondrial 
abnormalities in FA should take into account the stage 
of the disease process or the phenotypic expression of 
the disease since our study suggests that the abnor- 
malities may change with progression of the disease. 
We cannot exclude the possibility that an increased 
value for the lumped constant for fluorodeoxyglucose 
in FA could partially or completely account for our 
finding of increased lCMRglc values, which were cal- 
culated assuming a normal value for the lumped con- 
stant (0.51). An increase in the lumped constant for 
2-deoxyglucose has been described in hypoglycemia 
142, 431 and is thought to be due to a shift in the rate- 
limiting step from phosphorylation to transport. Con- 
ceivably, an increased value of the lumped constant 
in FA could share the same mechanism. Alterations in 
the lumped constant could influence our findings in 
either of two possible ways. First, the lumped constant 
could be increased in patients with early disease and 
could then decline with disease progression. This pos- 
sibility is unlikely because changes that may occur with 
disease progression, such as loss of neurons and synap- 
tic connections, would not be expected to reverse the 
change in the lumped constant substantially. Second, 
the lumped constant could be increased in all patients 
with FA, and the decrease in lCMRglc values in non- 
ambulatory patients compared with ambulatory pa- 
tients could represent a true decline in glucose metab- 
olism associated with loss of neuronal elements. 
The difference in metabolism between ambulatory 
and nonambulatory patients may be due to loss of 
neuronal connections as the disease progresses. Study 
of the degree of atrophy in ambulatory as compared 
with nonambulatory patients in anatomical scans would 
perhaps clarify this issue. The findings of glucose hy- 
permetabolism within certain structures in ambulatory 
but not in nonambulatory patients resulted from exam- 
ining a cross-section of patients. Our speculation that 
glucose metabolism decreases with progression of FA 
may be strengthened by longitudinal follow-up of indi- 
vidual patients with repeated testing. We have not 
studied patients with FA early in the disease process 
because our PET studies are limited to patients and 
normal subjects age 18 and older. From our present 
results, we cannot determine whether patients early 
in the course of FA have a greater degree or a lesser 
degree of hypermetabolism than our ambulatory 
group, most of whom are at an intermediate stage of 
the disease with a moderate level of disability. Simi- 
larly, our data do not make clear whether metabolism 
declines to a level below that of normal subjects. Ex- 
amination of patients with FA toward the end of their 
disease process would be necessary to establish this. 
In previous PET studies, the finding of glucose hy- 
permetabolism in steady state is unusual. Increased 
glucose metabolism has been reported in Down's syn- 
drome [44, 451, anorexia nervosa 1461, and autism 
f471, but in a recent report no definitive evidence of 
increased metabolism was found in autism {48], and 
the finding in Down's syndrome is now thought to be 
artifactual {491. Thus, FA is one of only a few condi- 
tions demonstrated through PET to involve hyper- 
metabolism in steady state. 
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